Multiple Myeloma Clinical Trials

167 studies are recruiting for multiple myeloma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

   This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Winship Cancer Institute of Emory University, Atlanta, Georgia

   Locations

   24 in total

   Run by

   Heidelberg Pharma AG

   See if you can join NCT04879043 on ClinicalTrials.gov

2. A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

   This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to pa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado

   Locations

   34 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04910568 on ClinicalTrials.gov

3. Collection of Tissue Samples for Cancer Research

   Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research …

   Stage

   Not phased

   Ages

   0 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   17 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00900198 on ClinicalTrials.gov

4. Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

   This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a sm…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Robert Flavell, MD, PhD

   See if you can join NCT05892393 on ClinicalTrials.gov

5. 18F-Fluciclovine PET/CT in Multiple Myeloma

   Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier. Objective: To find out if the radio…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06103838 on ClinicalTrials.gov

6. Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

   The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   8 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06976476 on ClinicalTrials.gov

7. Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities

   The objectives of the proposed study are to develop and evaluate protocols for ethnic/racial minority-specific research using cancer registry data. In conjunction with the Cancer Registry of Greater California (CRGC), the investigators have developed procedures to identify, recruit, and survey ethn…

   Stage

   Not phased

   Ages

   21 and older

   Site

   University of California Davis Comprehensive Cancer Center, Sacramento, California

   Run by

   University of California, Davis

   See if you can join NCT04314752 on ClinicalTrials.gov

8. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

9. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California /ID# 272414, Los Angeles, California

   Locations

   50 in total

   Run by

   AbbVie

   See if you can join NCT06953960 on ClinicalTrials.gov

10. Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

    Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality. The investigators hypothesize that a go-slow gentle approach to starting treatment in such patients, starting wit…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

    Run by

    University of Utah

    See if you can join NCT06517017 on ClinicalTrials.gov

11. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

    The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-C…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    75 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT07555938 on ClinicalTrials.gov

12. A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

    Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x clus…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile, Alabama

    Locations

    56 in total

    Run by

    Takeda

    See if you can join NCT06980480 on ClinicalTrials.gov

13. Tissue Collection for Studies of Lymph Cancer

    Background: - Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These condition…

    Stage

    Not phased

    Ages

    18 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Locations

    2 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT01676805 on ClinicalTrials.gov

14. A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

    This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM). The primary objective of this study is to evaluate the overall incidence of…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    6 in total

    Run by

    SCRI Development Innovations, LLC

    See if you can join NCT07637578 on ClinicalTrials.gov

15. A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

    The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    22 in total

    Run by

    Celgene

    See if you can join NCT06988488 on ClinicalTrials.gov

16. Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

    Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments. Objective…

    Stage

    Not phased

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT02682667 on ClinicalTrials.gov

17. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

    Stage

    Phase 2

    Ages

    12 and older

    Site

    University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama

    Locations

    181 in total

    Run by

    American Society of Clinical Oncology

    See if you can join NCT02693535 on ClinicalTrials.gov

18. Elranatamab in R/R Multiple Myeloma

    This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT06138275 on ClinicalTrials.gov

19. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

    The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona

    Locations

    50 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT05201781 on ClinicalTrials.gov

20. Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

    This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Illinois at Chicago, Chicago, Illinois

    Locations

    2 in total

    Run by

    University of Illinois at Chicago

    See if you can join NCT05344833 on ClinicalTrials.gov

21. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

    The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    270 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT05552222 on ClinicalTrials.gov

22. A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

    The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste ch…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California San Francisco, San Francisco, California

    Locations

    38 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT06500884 on ClinicalTrials.gov

23. A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

    The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilt…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    University of California San Francisco, San Francisco, California

    Locations

    17 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07149857 on ClinicalTrials.gov

24. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mayo Clinic Phoenix, Phoenix, Arizona

    Locations

    144 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07258511 on ClinicalTrials.gov

25. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refr…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Rocky Mountain Cancer Centers, Aurora, Colorado

    Locations

    71 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07266441 on ClinicalTrials.gov